Strides Pharma FY26 PAT Up 50% to ₹5,181m

Strides Pharma reported FY26 Operational PAT of ₹5,181m, a 50% YoY increase, with revenue growth of 6.4% to ₹48,587m.
EBITDA grew 15.3% to ₹9,253m, driven by 310bps gross margin expansion and strong 21% growth in Ex-US markets.
The Board recommended a dividend of ₹5 per share for FY26, while reported net debt stood at ₹14,365m with Net Debt/EBITDA of 1.55x.
The company outlined growth aspirations for North America to reach ~$400m by FY28 and announced the appointment of Ramaraju PVS as Executive Director.